<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069743</url>
  </required_header>
  <id_info>
    <org_study_id>13-080</org_study_id>
    <nct_id>NCT02069743</nct_id>
  </id_info>
  <brief_title>Pain Management in Cancer Patients Using a Mobile Application</brief_title>
  <acronym>ePAL</acronym>
  <official_title>Pain Management in Cancer Patients Using a Mobile Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McKesson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have developed a mobile application (for use on smart phones) to help&#xD;
      cancer patients better manage cancer pain. This study is a randomized controlled trial to&#xD;
      evaluate the effect of this mobile-based intervention. The investigators' hypothesis is that&#xD;
      subjects randomized to the intervention group will achieve greater reductions in&#xD;
      cancer-related pain and improved quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>8-weeks</time_frame>
    <description>The primary aim is to assess the effect of a tailored, multi-dimensional mobile-based intervention on the intensity of cancer pain in cancer patients with moderate to severe pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life survey</measure>
    <time_frame>4 &amp; 8-weeks</time_frame>
    <description>A secondary outcome will assess overall how patients feel about their cancer-related symptoms and treatments to address these symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital utilization for pain crisis</measure>
    <time_frame>4 and 8-weeks</time_frame>
    <description>In-patient and out-patient hospital visits&#xD;
Urgent non-scheduled clinic visits for pain crisis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily opioid consumption</measure>
    <time_frame>4 &amp; 8-weeks</time_frame>
    <description>Measured by oral morphine equivalent daily dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived barriers to cancer pain management</measure>
    <time_frame>4 &amp; 8-weeks</time_frame>
    <description>BQ-II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge of pain management</measure>
    <time_frame>4 &amp; 8-weeks</time_frame>
    <description>PPQ-K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement</measure>
    <time_frame>4 &amp; 8-weeks</time_frame>
    <description>Pattern of patient engagement with the study's mobile application</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will use the study's mobile application during the 8-week study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will not use the study's mobile application during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ePAL Mobile Application</intervention_name>
    <description>A mobile application designed to help cancer patients better self-manage cancer pain.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>ePAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult patients, 18 years and above suffering from solid-organ cancer.&#xD;
&#xD;
          -  Diagnosed with moderate or severe cancer pain (i.e. pain intensity score of at least&#xD;
             4/10 on numeric rating scale (NRS)) at the Massachusetts General Hospital (MGH)&#xD;
             Palliative Care Center, as determined by the patient's care provider at the MGH&#xD;
             Palliative Care Center. Subjects do not need to experience a specific nature of pain&#xD;
             for eligibility.&#xD;
&#xD;
          -  Patients must be ambulatory and not currently admitted to the hospital at time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Must have a smart phone and be willing to download the study application (Phase II&#xD;
             only)&#xD;
&#xD;
          -  Must be able to read and speak English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy less than 2-months as determined by the palliative care provider&#xD;
&#xD;
          -  Significant medical or psychiatric co-morbidities (other than depression or anxiety)&#xD;
             or cognitive impediments that would prevent participant from being able to utilize the&#xD;
             program&#xD;
&#xD;
          -  Known history of substance abuse&#xD;
&#xD;
          -  Patients currently on investigational therapies or other study protocols that may have&#xD;
             an impact on pain intensity or quality of life which are main outcomes of this&#xD;
             intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Jethwani, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mihir M. Kamdar,M.D.</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>cancer pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

